Loading provider…
Loading provider…
Gynecologic Oncology Physician in Tampa, FL
NPI: 1295740645Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get MD Robert's Phone Numberphone_androidMobile
Get MD Robert's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2004 - 2027
NC State Medical License
2001 - 2014

American Board of Obstetrics and Gynecology
Obstetrics & Gynecology

American Board of Obstetrics and Gynecology
Gynecologic Oncology
Duke University Hospital
Fellowship • Gynecologic Oncology
Until 2004
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital
Internship • Obstetrics and Gynecology
1997 - 2001
Residency • Obstetrics and Gynecology
Until 2001
UT Southwestern Medical Center
utsouthwestern.edu
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 26 | 37 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 15 | 17 |
| 3 | 99212Established patient outpatient visit, total time 10-19 minutes | 14 | 16 |
Authors: Melissa Geller, Floortje Backes, Pedro Ramirez
Journal: Am J Obstet Gynecol
Publication Date: 2017-10-14
Authors: Emily Mcclung, Jesus Gonzalez Bosquet, Hye Sook Chon
Journal: Int J Gynecol Cancer
The impact of distance to closest negative margin on survival after pelvic exenteration.
Authors: Ardeshir Hakam, Mian Shahzad, Hye Sook Chon, Mitchel Hoffman, Jing-Yi Chern
Journal: Gynecol Oncol
Publication Date: 2022-04-26
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Denosumab, PROCEDURE: Salpingo-Oophorectomy
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: Paclitaxel
Lead Sponsor: Prescient Therapeutics, Ltd.
Intervention / Treatment: DRUG: Carboplatin, DRUG: Triciribine